Hypera hires BR Partners to sell Xantinon brand

Hypera hires BR Partners to sell Xantinon brand

Corporate & Sovereign Strategy M&A Loans Brazil Latin America

Brazilian pharmaceutical company Hypera Pharma confirmed Monday that it hired BR Partners to arrange a possible sale of the Xantinon brand to keep antitrust authorities at bay after it closes an $825 million acquisition with Japan's Takeda Pharmaceutical Company. Local financial newspaper Valor Econômico reported on Friday that Hypera could earn up to BRL250 million ($48.6 million) from the sale Xantinon. The São Paulo-based drugmaker said in a securities filing on Monday that it had not settled

Already have an account?

Free trial

Take a free two-week trial now for the latest news, data and market analysis.

Free Trial